(Q44356040)

English

Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.

scientific article published in March 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 December 2017

Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. (English)

1 reference

Europe PubMed Central

2 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

Richard A. Larson

14

1 reference

Europe PubMed Central

2 December 2017

Clara D. Bloomfield

12

object named as

Clara D Bloomfield

1 reference

Europe PubMed Central

2 December 2017

8

object named as

David D Hurd

1 reference

Europe PubMed Central

2 December 2017

Jonathan E Kolitz

9

object named as

Jonathan E Kolitz

1 reference

Europe PubMed Central

2 December 2017

Charles A Schiffer

13

object named as

Charles A Schiffer

1 reference

Europe PubMed Central

2 December 2017

Enrique Velez-Garcia

10

object named as

Enrique Velez-Garcia

1 reference

Europe PubMed Central

2 December 2017

author name string

Ted P Szatrowski

1

1 reference

Europe PubMed Central

2 December 2017

Richard K Dodge

2

1 reference

Europe PubMed Central

2 December 2017

Carol Reynolds

3

1 reference

Europe PubMed Central

2 December 2017

Carol A Westbrook

4

1 reference

Europe PubMed Central

2 December 2017

Stanley R Frankel

5

1 reference

Europe PubMed Central

2 December 2017

Jeffrey Sklar

6

1 reference

Europe PubMed Central

2 December 2017

Carleton C Stewart

7

1 reference

Europe PubMed Central

2 December 2017

Richard M Stone

11

1 reference

Europe PubMed Central

2 December 2017

language of work or name

0 references

publication date

1 March 2003

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

97

1 reference

Europe PubMed Central

2 December 2017

6

1 reference

Europe PubMed Central

2 December 2017

1471-1480

1 reference

Europe PubMed Central

2 December 2017

The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid, nonradioactive detection of clonal T-cell receptor gene rearrangements in lymphoid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Monoclonal antibodies for treating cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Redesigning nature's poisons to create anti-tumor reagents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab: clinical development and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Campath-1H monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11219

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11219

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44356040&oldid=2118321216"